MVC Completed COVID-19 Vaccine Phase 2 Interim Safety Data Review Meeting
 MVC completed MVC CoV-1901 Vaccine Phase II Clinical trial’s Interim Independent Data Monitoring Committee (IDMC) meeting on May 8th, 2021. According to TFDA regulations, the safety results needed to be evaluated at this stage. So far there is no vaccine-related SAE (Serious Adverse Reaction), AESI (Adverse Events of Special Interest) and VAED (Vaccine-associated Enhanced Disease) are observed.
In the Interim IDMC meeting, the committee concluded that there is no major safety issues and has agreed to initiate new clinical trial for adolescents (12~18 years old) in accordance with TFDA regulations. MVC will apply indication to adolescent subjects after completing this new clinical trial.